Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biosimilar offers hope for wet AMD patients

NCT ID NCT07235527

Disease control Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study looks at how well a biosimilar drug called Yesafili works for people with wet age-related macular degeneration (AMD). About 54 participants will switch from the standard drug Eylea to Yesafili. Doctors will check vision and eye health to see if the biosimilar is a safe and effective alternative.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

54 people

The number who actually took part.

Started

Nov 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 45 to 90 years diagnosed with active neovascular (exudative) age-related macular degeneration (nAMD), who are receiving routine ophthalmologic follow-up at a tertiary referral center and have been clinically indicated for intravitreal aflibercept biosimilar (MY-1701P) injection. Participants will be selected based on evidence of disease activity on ophthalmologic examination and optical coherence tomography (OCT) imaging.

Ages

45 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD) * who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT) * for whom intravitreal injection has already been clinically indicated Exclusion Criteria: * Patients younger than 45 years or older than 90 years * History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months * Presence of uveitis * Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract) * Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema) * Presence of hereditary retinal dystrophies * Presence of optic atrophy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Anti vascular endothelial growth factor Exudative age-related macular degeneration

Contacts and locations

Locations

  • Prof. Dr. Cemil Taşcıoğlu City Hospital

    Istanbul, şişli, 34384, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.